D Hess
Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). Br J Clin Pharmacol 2015; 80:128-38.
03.06.2015Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
03.06.2015Br J Clin Pharmacol 2015; 80:128-38
Joerger M, Hess D, Delmonte Angelo, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
Joerger M, Hess D, Delmonte A, Gallerani E, Barbieri P, Pace S, Sessa C. Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors. Invest New Drugs 2015; 33:472-9.
20.02.2015Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
20.02.2015Invest New Drugs 2015; 33:472-9
Joerger M, Hess D, Delmonte Angelo, Gallerani E, Barbieri P, Pace S, Sessa C
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors
Sessa C, Marsoni S, Zanna C, Carminati P, Gatti B, Capri G, Zaniboni A, D'Incalci M, Zucchetti M, Trigo J, Hess D, Malossi A, Rota Caremoli E, Baselga J, Cerny T, Cresta S, Gianni L. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18:561-8.
01.03.2007Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors
01.03.2007Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18:561-8
Sessa C, Marsoni S, Zanna C, Carminati P, Gatti B, Capri G, Zaniboni A, D'Incalci M, Zucchetti M, Trigo J, Hess D, Malossi A, Rota Caremoli E, Baselga J, Cerny Thomas, Cresta S, Gianni L
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
Pagani O, Longhi S, Ruggeri M, Graffeo R, Hess D, Thürlimann B, Lombardi D, Crivellari D, Munzone E, Nolé F, Sessa C, Goldhirsch A. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. Ann Oncol 2005; 16:1609-17.
01.10.2005Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
01.10.2005Ann Oncol 2005; 16:1609-17
Pagani O, Longhi S, Ruggeri M, Graffeo R, Hess D, Thürlimann Beat, Lombardi D, Crivellari D, Munzone E, Nolé F, Sessa C, Goldhirsch A